Although many studies have investigated the utility of measuring PD-L1 expression as a predictor of response to anti-PD-1 agents, it has been concluded that, in melanoma patients, the low or negative expression does not exclude a response to this type of immunotherapy [14,15]. The gene discussed is CD274; the disease is melanoma.